{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:43Z","timestamp":1788437923930,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170644"],"award-info":[{"award-number":["82170644"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR23H020001"],"award-info":[{"award-number":["LR23H020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16294-7","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:28:16Z","timestamp":1782127696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Siqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"1","key":"16294_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.","journal-title":"Blood Cancer J"},{"issue":"3","key":"16294_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"16294_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrclinonc.2012.91","volume":"9","author":"P Borchmann","year":"2012","unstructured":"Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450\u20139.","journal-title":"Nat Rev Clin Oncol"},{"issue":"27","key":"16294_CR4","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938\u201348.","journal-title":"J Clin Oncol"},{"issue":"19","key":"16294_CR5","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/cncr.30791","volume":"123","author":"TB Alexander","year":"2017","unstructured":"Alexander TB, Wang L, Inaba H, Triplett BM, Pounds S, Ribeiro RC, et al. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer. 2017;123(19):3791\u20138.","journal-title":"Cancer"},{"issue":"14","key":"16294_CR6","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1200\/JCO.2010.32.8427","volume":"29","author":"AK Ng","year":"2011","unstructured":"Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011;29(14):1885\u201392.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16294_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5306\/wjco.v12.i3.144","volume":"12","author":"T Mohammed","year":"2021","unstructured":"Mohammed T, Parekh T, Desai A. Cardiovascular risk management in cancer survivors: are we doing it right? World J Clin Oncol. 2021;12(3):144\u20139.","journal-title":"World J Clin Oncol"},{"issue":"1\u20132","key":"16294_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ppedcard.2014.09.003","volume":"36","author":"GT Armstrong","year":"2014","unstructured":"Armstrong GT, Ross JD. Late cardiotoxicity in aging adult survivors of childhood cancer. Prog Pediatr Cardiol. 2014;36(1\u20132):19\u201326.","journal-title":"Prog Pediatr Cardiol"},{"key":"16294_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","volume":"185","author":"WCM Dempke","year":"2023","unstructured":"Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle? Eur J Cancer. 2023;185:94\u2013104.","journal-title":"Eur J Cancer"},{"issue":"4","key":"16294_CR10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/bloodadvances.2019000955","volume":"4","author":"NR Neuendorff","year":"2020","unstructured":"Neuendorff NR, Loh KP, Mims AS, Christofyllakis K, Soo WK, Bolukbasi B, et al. Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper. Blood Adv. 2020;4(4):762\u201375.","journal-title":"Blood Adv"},{"issue":"8","key":"16294_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-021-00868-7","volume":"22","author":"P Ell","year":"2021","unstructured":"Ell P, Martin JM, Cehic DA, Ngo DTM, Sverdlov AL. Cardiotoxicity of radiation therapy: mechanisms, management, and mitigation. Curr Treat Options Oncol. 2021;22(8):70.","journal-title":"Curr Treat Options Oncol"},{"issue":"15","key":"16294_CR12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"key":"16294_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"9","key":"16294_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"29","key":"16294_CR15","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/sim.5453","volume":"31","author":"D Jackson","year":"2012","unstructured":"Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31(29):3805\u201320.","journal-title":"Stat Med"},{"issue":"7109","key":"16294_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"4","key":"16294_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"1","key":"16294_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mayocp.2015.09.009","volume":"91","author":"SG Al-Kindi","year":"2016","unstructured":"Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016;91(1):81\u20133.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"16294_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104\u201314.","journal-title":"Circulation"},{"issue":"3","key":"16294_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jnci\/djk029","volume":"99","author":"AJ Swerdlow","year":"2007","unstructured":"Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"16294_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.clon.2004.09.016","volume":"17","author":"AM Gaya","year":"2005","unstructured":"Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol). 2005;17(3):153\u20139.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"41","key":"16294_CR22","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"23","key":"16294_CR23","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","volume":"61","author":"C Jaworski","year":"2013","unstructured":"Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"16294_CR24","doi-asserted-by":"publisher","unstructured":"Prasad RN, McIntyre M, Guha A, Carter RR, Yildiz VO, Paskett E, Lustberg M, Ruz P, Williams TM, Kola-Kehinde O, et al. Cardiovascular event reporting in modern cancer radiation therapy trials. Adv Radiation Oncol. 2022;7(2):100888. https:\/\/doi.org\/10.1016\/j.adro.2021.100888.","DOI":"10.1016\/j.adro.2021.100888"},{"key":"16294_CR25","doi-asserted-by":"publisher","unstructured":"Vakilpour A, Lefebvre B, Lai C, Scherrer-Crosbie M. Heartbreaker: detection and prevention of cardiotoxicity in hematological malignancies. Blood Rev. 2024;64:101166. https:\/\/doi.org\/10.1016\/j.blre.2023.101166.","DOI":"10.1016\/j.blre.2023.101166"},{"key":"16294_CR26","doi-asserted-by":"publisher","unstructured":"Shell D. Cardiac surgery for radiation associated heart disease in Hodgkin lymphoma patients. Best Pract Res Clin Haematol. 2023;36(4):101515. https:\/\/doi.org\/10.1016\/j.beha.2023.101515.","DOI":"10.1016\/j.beha.2023.101515"},{"issue":"4","key":"16294_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3109\/10428190109099323","volume":"42","author":"A Avil\u00e9s","year":"2001","unstructured":"Avil\u00e9s A, D\u00edaz-Maqueo JC, Garc\u00eda EL, Talavera A, Huerta-Guzm\u00e1n J, Neri N. Late lethal events in patients with diffuse large B cell lymphoma: a review of 714 patients treated in a single centre. Leuk Lymphoma. 2001;42(4):631\u20137.","journal-title":"Leuk Lymphoma"},{"key":"16294_CR28","doi-asserted-by":"crossref","unstructured":"van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers JMM, Kok WEM, Aleman BMP, van Leeuwen FE. Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med. 2015;175(6):1007\u201317.","DOI":"10.1001\/jamainternmed.2015.1180"},{"issue":"2","key":"16294_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.radonc.2011.08.040","volume":"101","author":"L Cella","year":"2011","unstructured":"Cella L, Liuzzi R, Conson M, Torre G, Caterino M, De Rosa N, et al. Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin\u2019s lymphoma. Radiother Oncol. 2011;101(2):316\u201321.","journal-title":"Radiother Oncol"},{"issue":"33","key":"16294_CR30","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1200\/JCO.20.00935","volume":"38","author":"A Gallamini","year":"2020","unstructured":"Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL\/FIL HD0607 trial. J Clin Oncol. 2020;38(33):3905\u201313.","journal-title":"J Clin Oncol"},{"issue":"4","key":"16294_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/pbc.22908","volume":"56","author":"P Temming","year":"2011","unstructured":"Temming P, Qureshi A, Hardt J, Leiper AD, Levitt G, Ancliff PJ, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer. 2011;56(4):625\u201330.","journal-title":"Pediatr Blood Cancer"},{"key":"16294_CR32","doi-asserted-by":"publisher","first-page":"134679","DOI":"10.4061\/2011\/134679","volume":"2011","author":"VI Franco","year":"2011","unstructured":"Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract. 2011;2011:134679.","journal-title":"Cardiol Res Pract"},{"key":"16294_CR33","doi-asserted-by":"crossref","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229.","DOI":"10.1124\/pr.56.2.6"},{"issue":"4","key":"16294_CR34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1055\/s-2008-1043814","volume":"211","author":"B Zalewska-Szewczyk","year":"1999","unstructured":"Zalewska-Szewczyk B, Lipiec J, Bodalski J. Late cardiotoxicity of anthracyclines in children with acute leukemia. Klin Padiatr. 1999;211(4):356\u20139.","journal-title":"Klin Padiatr"},{"issue":"2","key":"16294_CR35","doi-asserted-by":"publisher","first-page":"e2254669","DOI":"10.1001\/jamanetworkopen.2022.54669","volume":"6","author":"CM Larsen","year":"2023","unstructured":"Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985\u20132010. JAMA Netw Open. 2023;6(2):e2254669.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"16294_CR36","first-page":"1058","volume":"50","author":"MY Dai","year":"2022","unstructured":"Dai MY, Zhang YL, Sun YX, Lyu X, Zhang XX, Sun XL, et al. Cardiovascular events and risk factors in hematological neoplasms patients treated with anthracyclines. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50(11):1058\u201363.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"16294_CR37","doi-asserted-by":"crossref","unstructured":"Armenian SH, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteer JD, Mascarenhas L, et al. Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. Cancer Epidemiol Biomarkers Prev. 2014;23(6):1109\u201314.","DOI":"10.1158\/1055-9965.EPI-13-1384"},{"issue":"3","key":"16294_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00246-010-9878-3","volume":"32","author":"BH Trachtenberg","year":"2011","unstructured":"Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011;32(3):342\u201353.","journal-title":"Pediatr Cardiol"},{"key":"16294_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1047951115000906","volume":"25","author":"VI Franco","year":"2015","unstructured":"Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25:107\u201316.","journal-title":"Cardiol Young"},{"issue":"8","key":"16294_CR40","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","volume":"13","author":"N Bansal","year":"2017","unstructured":"Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol. 2017;13(8):817\u201332.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"16294_CR41","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1002\/cam4.1754","volume":"7","author":"D Schoormans","year":"2018","unstructured":"Schoormans D, Vissers PAJ, van Herk-Sukel MPP, Denollet J, Pedersen SS, Dalton SO, et al. Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors. Cancer Med. 2018;7(10):4952\u201363.","journal-title":"Cancer Med"},{"key":"16294_CR42","doi-asserted-by":"crossref","unstructured":"Hau EM, Caccia JN, Kasteler R, Spycher B, Suter T, Ammann RA, von der Weid NX, Kuehni CE. Cardiovascular disease after childhood acute lymphoblastic leukaemia: a cohort study. Swiss Med Wkly. 2019;149:w20012.","DOI":"10.4414\/smw.2019.20012"},{"issue":"4","key":"16294_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11936-016-0447-9","volume":"18","author":"A Blaes","year":"2016","unstructured":"Blaes A, Konety S, Hurley P. Cardiovascular complications of hematopoietic stem cell transplantation. Curr Treat Options Cardiovasc Med. 2016;18(4):25.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"6","key":"16294_CR44","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.bbmt.2016.02.017","volume":"22","author":"KJ Leger","year":"2016","unstructured":"Leger KJ, Cushing-Haugen K, Hansen JA, Fan W, Leisenring WM, Martin PJ, et al. Clinical and genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2016;22(6):1094\u2013101.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"16294_CR45","doi-asserted-by":"publisher","first-page":"16829","DOI":"10.1038\/s41598-024-65294-9","volume":"14","author":"S Krishan","year":"2024","unstructured":"Krishan S, Asad ZUA, Quiroga D, Ghazi SM, Quartermaine C, Braunstein Z, et al. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample. Sci Rep. 2024;14(1):16829.","journal-title":"Sci Rep"},{"key":"16294_CR46","doi-asserted-by":"crossref","unstructured":"Zhao Y, He R, Oerther S, Zhou W, Vosough M, Hassan M. Cardiovascular complications in hematopoietic stem cell transplanted patients. J Pers Med. 2022;12(11):1797.","DOI":"10.3390\/jpm12111797"},{"issue":"9","key":"16294_CR47","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/echo.13278","volume":"33","author":"V Schiano-Lomoriello","year":"2016","unstructured":"Schiano-Lomoriello V, Galderisi M, Mele D, Esposito R, Cerciello G, Buonauro A, et al. Longitudinal strain of left ventricular basal segments and E\/e\u2019 ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography. 2016;33(9):1335\u201343.","journal-title":"Echocardiography"},{"issue":"2","key":"16294_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ejh.70060","volume":"116","author":"M Picardi","year":"2026","unstructured":"Picardi M, Vincenzi A, Giordano C, Pugliese N, Scarpa A, Lombardi A, et al. Brentuximab Vedotin with Adriamycin, Vinblastine, and Dacarbazine for patients aged 18\u201359 years with untreated advanced stage classical Hodgkin lymphoma: The largest real-life series from Southern Italy cancer centers. Eur J Haematol. 2026;116(2):174\u201384.","journal-title":"Eur J Haematol"},{"issue":"10","key":"16294_CR49","doi-asserted-by":"publisher","first-page":"e70240","DOI":"10.1002\/hem3.70240","volume":"9","author":"M Picardi","year":"2025","unstructured":"Picardi M, Vincenzi A, Pugliese N, Giordano C, Prastaro M, Esposito R, et al. Liposomal doxorubicin in place of doxorubicin hydrochloride to prevent anthracycline-induced cardiomyopathy in elderly patients with Hodgkin lymphoma. Hemasphere. 2025;9(10):e70240.","journal-title":"Hemasphere"},{"issue":"6","key":"16294_CR50","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/hon.70003","volume":"42","author":"M Picardi","year":"2024","unstructured":"Picardi M, Vincenzi A, Giordano C, Fazio L, Pugliese N, Scarpa A, et al. Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study. Hematol Oncol. 2024;42(6):e70003.","journal-title":"Hematol Oncol"},{"issue":"5","key":"16294_CR51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F, et al. Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. Br J Haematol. 2022;198(5):847\u201360.","journal-title":"Br J Haematol"},{"key":"16294_CR52","doi-asserted-by":"crossref","unstructured":"Berkman AM, Brewster AM, Jones LW, Yu J, Lee JJ, Peng SA, Crocker A, Ater JL, Gilchrist SC. Racial differences in 20-year cardiovascular mortality risk among childhood and young adult cancer survivors. J Adolesc Young Adult Oncol. 2017;6(3):414\u201321.","DOI":"10.1089\/jayao.2017.0024"},{"key":"16294_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2023.11.039","volume":"212","author":"JH Yong","year":"2024","unstructured":"Yong JH, Mai AS, Matetic A, Elbadawi A, Elgendy IY, Lopez-Fernandez T, et al. Cardiovascular risk in patients with hematological malignancies: a systematic review and meta-analysis. Am J Cardiol. 2024;212:80\u2013102.","journal-title":"Am J Cardiol"},{"issue":"10","key":"16294_CR54","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","volume":"34","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016;34(10):1122\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16294_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","volume":"4","author":"DI Paterson","year":"2022","unstructured":"Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, et al. Incident cardiovascular disease among adults with cancer: a population-based cohort study. JACC CardioOncol. 2022;4(1):85\u201394.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"16294_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","volume":"80","author":"R Florido","year":"2022","unstructured":"Florido R, Daya NR, Ndumele CE, Koton S, Russell SD, Prizment A, et al. Cardiovascular disease risk among cancer survivors. J Am Coll Cardiol. 2022;80(1):22\u201332.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16294-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:02:22Z","timestamp":1788436942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16294-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16294"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16294-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1042"}}